KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Cash from Investing Activities (2016 - 2026)

Amgen has reported Cash from Investing Activities over the past 18 years, most recently at -$716.0 million for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 60.18% year-over-year to -$716.0 million; the TTM value through Mar 2026 reached -$2.2 billion, down 73.35%, while the annual FY2025 figure was -$1.9 billion, 85.76% down from the prior year.
  • Cash from Investing Activities for Q1 2026 was -$716.0 million at Amgen, down from -$693.0 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $1.4 billion in Q1 2023 and troughed at -$27.1 billion in Q4 2023.
  • A 5-year average of -$2.1 billion and a median of -$389.0 million in 2025 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 1410.0% in 2022 and later soared 1323.42% in 2023.
  • Year by year, Cash from Investing Activities stood at -$3.5 billion in 2022, then crashed by 679.99% to -$27.1 billion in 2023, then soared by 98.52% to -$402.0 million in 2024, then plummeted by 72.39% to -$693.0 million in 2025, then fell by 3.32% to -$716.0 million in 2026.
  • Business Quant data shows Cash from Investing Activities for AMGN at -$716.0 million in Q1 2026, -$693.0 million in Q4 2025, and -$414.0 million in Q3 2025.